Alpha Teknova (NASDAQ:TKNO) Announces Earnings Results, Beats Estimates By $0.02 EPS

Alpha Teknova (NASDAQ:TKNO) announced its earnings results on Wednesday. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02, FiscalAI reports. The company had revenue of $12.19 million during the quarter, compared to analysts’ expectations of $10.95 million. Alpha Teknova had a negative return on equity of 24.32% and a negative net margin of 41.07%.

Here are the key takeaways from Alpha Teknova’s conference call:

• Second-quarter revenue rose 18% to a record $12 million, with growth broad-based across customers and major markets aside from cell and gene therapy. Gross margin improved to 40.1%, while free cash outflow declined sharply to $0.6 million from $2.3 million a year earlier.
• Teknova raised 2026 revenue guidance to $45 million-$47 million, implying approximately 14% growth at the midpoint, and now expects full-year free cash outflow below $8 million.
• Management cited potential longer-term growth from more than 70 therapies and diagnostics in clinical trials, improving biotech funding, and commercial investments, but said the funding benefit has not yet reached revenue and expects most sales impact from the commercial buildout in early 2027.
• Cell and gene therapy demand remains muted, while operating expenses are expected to remain at least $8 million per quarter through year-end. The company still expects adjusted EBITDA to turn positive only after reaching approximately $52 million-$57 million in annualized revenue, and its 2027 target remains in the low-$50-million range.
• The company officially launched Build-Tek, an AI-powered custom-product configurator intended to shorten custom order design from weeks to a few business days and encourage catalog customers to adopt higher-value custom products; management expects it to support growth rather than generate direct software fees.

Alpha Teknova Stock Up 16.4%

Shares of TKNO stock traded up $0.92 during trading hours on Thursday, reaching $6.53. 384,079 shares of the stock were exchanged, compared to its average volume of 186,584. The business’s fifty day moving average is $5.17 and its two-hundred day moving average is $3.71. The firm has a market capitalization of $350.10 million, a P/E ratio of -20.41 and a beta of 0.64. Alpha Teknova has a 12-month low of $1.91 and a 12-month high of $6.68. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.59 and a quick ratio of 3.60.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Alpha Teknova in the 2nd quarter valued at $29,000. JPMorgan Chase & Co. grew its stake in shares of Alpha Teknova by 123.1% during the second quarter. JPMorgan Chase & Co. now owns 8,163 shares of the company’s stock worth $40,000 after purchasing an additional 4,504 shares in the last quarter. Larson Financial Group LLC increased its holdings in Alpha Teknova by 58.5% in the third quarter. Larson Financial Group LLC now owns 9,387 shares of the company’s stock valued at $58,000 after buying an additional 3,464 shares during the last quarter. XTX Topco Ltd purchased a new position in Alpha Teknova in the fourth quarter valued at $77,000. Finally, Sherbrooke Park Advisers LLC acquired a new stake in Alpha Teknova in the third quarter valued at $94,000. Institutional investors and hedge funds own 13.81% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TKNO. Roth Capital started coverage on shares of Alpha Teknova in a research note on Wednesday. They issued a “buy” rating and a $7.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Teknova in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $7.00.

About Alpha Teknova

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.